Valneva vs Abivax SA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Valneva SE (VLA.PA)

Q3 202613 Aug – 8 Oct 2026

▼2▲1

Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh

Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.
This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.
UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.
This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.
First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.
The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.
Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.
It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.

September 202613 Aug – 8 Oct 2026

▼2▲1

Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh

Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.
This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.
UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.
This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.
First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.
The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.
Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.
It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.

Latest13 Aug – 8 Oct 2026

▼2▲1

Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh

Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.
This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.
UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.
This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.
First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.
The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.
Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.
It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.

Abivax SA (ABVX.PA)

Q2 202617 Jun – 1 Jul 2026

▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.
This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.
Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.
This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.
Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.
This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.
Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.
This is a negative factor that could pressure the stock, providing a balanced view of risks.

June 202617 Jun – 1 Jul 2026

▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.
This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.
Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.
This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.
Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.
This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.
Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.
This is a negative factor that could pressure the stock, providing a balanced view of risks.

Latest17 Jun – 1 Jul 2026

▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.
This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.
Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.
This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.
Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.
This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.
Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.
This is a negative factor that could pressure the stock, providing a balanced view of risks.